{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:13:58Z","timestamp":1787066038385,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian Pediatr"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s13312-021-2096-7","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T22:11:41Z","timestamp":1611785501000},"page":"44-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2020\u201321) and Update on Immunization for Children Aged 0 Through 18 Years"],"prefix":"10.1007","volume":"58","author":[{"given":"Srinivas G.","family":"Kasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shivananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kripasindhu","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Agarwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi Kant","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Srirampur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Kalyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish Kumar","family":"Pemde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakul J.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Basavaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,29]]},"reference":[{"key":"2096_CR1","unstructured":"GPEI-How India Eradicated Polio [Internet]. [cited 2020 Nov 23]. Available from: https:\/\/polioeradication.org\/news-post\/how-india-eradicated-polio-challenges-and-lessons-learned\/"},{"issue":"69","key":"2096_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.15585\/mmwr.mm6925a4","volume":"26","author":"AN Chard","year":"2020","unstructured":"Chard AN, Datta SD, Tallis G, et al. Progress Toward Polio Eradication \u2014 Worldwide, January 2018-March 2020. MMWR Morb Mortal Wkly Rep. 2020 26;69:784\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s13312-018-1444-8","volume":"55","author":"S Balasubramanian","year":"2018","unstructured":"Balasubramanian S, Shah A, Pemde HK, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) Recommended Immunization Schedule (2018\u201319) and Update on Immunization for Children Aged 0 Through 18 Years. Indian Pediatr. 2018;55:1066\u201374.","journal-title":"Indian Pediatr"},{"key":"2096_CR4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/B978-0-323-35761-6.00047-X","volume-title":"Plotkin\u2019s Vaccines","author":"Vidor Emmanuel","year":"2018","unstructured":"Emmanuel Vidor. Polio vaccines- Inactivated. In: Plotkin SA, Offit PA, Orenstein WA, Edwards KM editors. Plotkin\u2019s Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p.841\u201365.","edition":"7th ed"},{"key":"2096_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vaccine.2008.10.061","volume":"27","author":"MB Rennels","year":"2009","unstructured":"Rennels MB. Need for polio boosters after age two years. Vaccine. 2009;27:179\u201380.","journal-title":"Vaccine"},{"key":"2096_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.vaccine.2003.10.025","volume":"22","author":"E Mallet","year":"2004","unstructured":"Mallet E, Matisse N, Mathieu N, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5\u20136-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine. 2004;22:1415\u201322.","journal-title":"Vaccine"},{"issue":"11\u201312","key":"2096_CR7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.vaccine.2003.10.026","volume":"22","author":"J Langue","year":"2004","unstructured":"Langue J, Matisse N, Pacoret P, et al. Persistence of antibodies at 5\u20136 years of age for children who had received a primary series vaccination with a pentavalent wholecell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5\u20136 years of age. Vaccine. 2004 Mar 29;22(11\u201312):1406\u201314.","journal-title":"Vaccine"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1016\/j.vaccine.2015.06.105","volume":"33","author":"T John","year":"2015","unstructured":"John T, Voysey M, Yu LM, et al. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study. Vaccine. 2015;33:4579\u201385.","journal-title":"Vaccine"},{"key":"2096_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4161\/hv.6.2.10117","volume":"6","author":"M Zinke","year":"2010","unstructured":"Zinke M, Disselhoff J, DTP a-HBV-IPV-110 and -111 study groups, Gartner B, Jacquet J-M. Immunological persistence in 4\u20136 and 7\u20139 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV\/Hib. Hum Vaccin. 2010;6:189\u201393.","journal-title":"Hum Vaccin"},{"key":"2096_CR10","unstructured":"Persistence of protective antibodies following immunization with IPV. Accessed on October 27, 2020. Available at https:\/\/www.who.int\/immunization\/polio_grad_duration_protectionpdf?ua=1#:~:text=High%20scientific%20evidence%20for%20%E2%89%A5,%2D%E2%80%90%204%20doses%20of%20OPV.&text=of%20OPV%20in%2067%20children,all%20three%20types%20of%20poliovirus"},{"key":"2096_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/oxfordjournals.aje.a121058","volume":"90","author":"WP Glezen","year":"1969","unstructured":"Glezen WP, McCollough RH, Lamb GA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol. 1969;90:146\u201356.","journal-title":"Am J Epidemiol"},{"key":"2096_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1086\/427810","volume":"191","author":"F Abbink","year":"2005","unstructured":"Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MAE. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005;191:990\u20139.","journal-title":"J Infect Dis"},{"key":"2096_CR13","first-page":"681","volume":"90","author":"Meeting of the Strategic Advisory Group of Experts on immunization","year":"2015","unstructured":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 \u2014 conclusions and recommendations. Releve Epidemiol Hebd. 2015;90:681\u201399.","journal-title":"Releve Epidemiol Hebd"},{"issue":"Suppl1","key":"2096_CR14","doi-asserted-by":"publisher","first-page":"S475","DOI":"10.1093\/infdis\/jit845","volume":"210","author":"KM Thompson","year":"2014","unstructured":"Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210 Suppl 1:S475\u2013484.","journal-title":"J Infect Dis"},{"key":"2096_CR15","unstructured":"UNICEF, WHO. Progress and Challenges with Achieving Universal Immunization Coverage [Internet]. [cited 2020 Oct 30]. Available from: https:\/\/www.who.int\/publications\/m\/item\/progress-and-challenges-with-achievinguniversalimmunizationcoverage"},{"key":"2096_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/infdis\/jiz124","volume":"220","author":"DTT Huyen","year":"2019","unstructured":"Huyen DTT, Mach O, Thanh Trung N, et al. Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam. J Infect Dis. 2019; 220:386\u201391.","journal-title":"J Infect Dis"},{"key":"2096_CR17","doi-asserted-by":"crossref","unstructured":"Yan D, Wang D, Zhang Y, et al. Implication of a High Risk of Type 2 Vaccine-Derived Poliovirus Emergence and Transmission after the Switch from tOPV to bOPV. J Infect Dis. 2020; jiaa386.","DOI":"10.1093\/infdis\/jiaa386"},{"key":"2096_CR18","unstructured":"GPEI-Circulating vaccine-derived poliovirus [Internet]. [cited 2020 Oct 30]. Available from: https:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/circulating-vaccine-derived-poliovirus\/"},{"key":"2096_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/infdis\/134.6.633","volume":"134","author":"PF Wright","year":"1976","unstructured":"Wright PF, Dolin R, La Montagne JR. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines-II. J Infect Dis. 1976; 134:633\u20138.","journal-title":"J Infect Dis"},{"key":"2096_CR20","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1016\/j.vaccine.2010.04.058","volume":"28","author":"EB Walter","year":"2010","unstructured":"Walter EB, Rajagopal S, Zhu Y, Neuzil KM, Fairchok MP, Englund JA. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine. 2010; 28:4376\u201383.","journal-title":"Vaccine"},{"key":"2096_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","volume":"30","author":"S Black","year":"2011","unstructured":"Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30: 1081\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"2096_CR22","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1542\/peds.2010-2777","volume":"128","author":"DM Skowronski","year":"2011","unstructured":"Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011;128:e276\u2013289.","journal-title":"Pediatrics"},{"key":"2096_CR23","first-page":"9","volume":"6","author":"VK Jain","year":"2017","unstructured":"Jain VK, Domachowske JB, Wang L, et al. Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial. J Pediatr Infect Dis Soc. 2017;6:9\u201319.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2096_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/INF.0000000000002227","volume":"38","author":"CA Robertson","year":"2019","unstructured":"Robertson CA, Mercer M, Selmani A, Klein NP, Jeanfreau R, Greenberg DP. Safety and Immunogenicity of a Full-dose, Splitvirion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6\u201335 Months of Age: A Randomized Controlled Clinical Trial. Pediatr Infect Dis J. 2019;38:323\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"2096_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S2352-4642(18)30062-2","volume":"2","author":"C Claeys","year":"2018","unstructured":"Claeys C, Zaman K, Dbaibo G, et al. Prevention of vaccine-matched and mismatched influenza in children aged 6\u201335 months: a multinational randomised trial across five influenza seasons. Lancet Child Adolesc Health. 2018;2:338\u201349.","journal-title":"Lancet Child Adolesc Health"},{"key":"2096_CR26","unstructured":"Influvac Tetra 2020\/2021 Product Information. Accessed on October 27, 2020. Available at: https:\/\/www.mylan.ca\/-\/media\/mylanca\/documents\/english\/product-pdf\/influvac-tetra-pm-en.pdf?la=en-ca"},{"key":"2096_CR27","unstructured":"FLUARIX-TETRA 2020\/2021 North. Product information. Assessed on October 27,2020. Available at https:\/\/india-pharma.gsk.com\/media\/850622\/fluarix-tetra.pdf"},{"key":"2096_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/infdis\/172.1.217","volume":"172","author":"B Watson","year":"1995","unstructured":"Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 1995; 172:217\u20139.","journal-title":"J Infect Dis"},{"key":"2096_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/infdis\/171.1.13","volume":"171","author":"S Nader","year":"1995","unstructured":"Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis. 1995;171:13\u20137.","journal-title":"J Infect Dis"},{"key":"2096_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","volume":"23","author":"B Kuter","year":"2004","unstructured":"Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"2096_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00006454-199601000-00011","volume":"15","author":"AL Ngai","year":"1996","unstructured":"Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immuno-genicity of one vs. two injections of Oka\/Merck varicella vaccine in healthy children. Pediatr Infect Dis J. 1996;15:49\u201354.","journal-title":"Pediatr Infect Dis J"},{"key":"2096_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/01.inf.0000172902.25009.a1","volume":"24","author":"H Shinefield","year":"2005","unstructured":"Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24:665\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"2096_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1542\/peds.100.5.761","volume":"100","author":"CE Johnson","year":"1997","unstructured":"Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics. 1997;100:761\u20136.","journal-title":"Pediatrics"},{"key":"2096_CR34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1542\/peds.75.4.667","volume":"75","author":"Y Asano","year":"1985","unstructured":"Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics. 1985;75:667\u201371.","journal-title":"Pediatrics"},{"key":"2096_CR35","doi-asserted-by":"publisher","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","volume":"131","author":"R Baxter","year":"2013","unstructured":"Baxter R, Ray P, Tran TN, et al. Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics. 2013;131:e1389\u20131396.","journal-title":"Pediatrics"},{"key":"2096_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.291.7.851","volume":"291","author":"M V\u00e1zquez","year":"2004","unstructured":"V\u00e1zquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851\u20135.","journal-title":"JAMA"},{"key":"2096_CR37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/INF.0b013e3181d7380e","volume":"29","author":"C Fu","year":"2010","unstructured":"Fu C, Wang M, Liang J, Xu J, Wang C, Bialek S. The effectiveness of varicella vaccine in China. Pediatr Infect Dis J. 2010;29:690\u20133.","journal-title":"Pediatr Infect Dis J"},{"key":"2096_CR38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMoa064040","volume":"356","author":"SS Chaves","year":"2007","unstructured":"Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007;356: 1121\u20139.","journal-title":"N Engl J Med"},{"key":"2096_CR39","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1016\/j.vaccine.2007.07.010","volume":"25","author":"O Bayer","year":"2007","unstructured":"Bayer O, Heininger U, Heiligensetzer C, von Kries R. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine. 2007; 25:6655\u201360.","journal-title":"Vaccine"},{"key":"2096_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","volume":"15","author":"FH Varela","year":"2019","unstructured":"Varela FH, Pinto LA, Scotta MC. Global impact of varicella vaccination programs. Hum Vaccines Immunother. 2019;15: 645\u201357.","journal-title":"Hum Vaccines Immunother"},{"key":"2096_CR41","unstructured":"Menveo product monogram. Accessed on July 21 2020. Available at https:\/\/india-pharma.gsk.com\/media\/870843\/menveo.pdf"},{"key":"2096_CR42","doi-asserted-by":"publisher","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","volume":"28","author":"SA Halperin","year":"2010","unstructured":"Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age. Vaccine. 2010;28:7865\u201372.","journal-title":"Vaccine"},{"key":"2096_CR43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1086\/599117","volume":"49","author":"LA Jackson","year":"2009","unstructured":"Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49:e1\u201310.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2096_CR44","first-page":"36","volume":"38","author":"S Lalwani","year":"2015","unstructured":"Lalwani S, Agarkhedkar S, Gogtay N, et al. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2015;38:36\u201342.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"2096_CR45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s13312-014-0504-y","volume":"51","author":"VM Vashishtha","year":"2014","unstructured":"Vashishtha VM, Choudhury P, Kalra A, et al. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years-India, 2014 and updates on immunization. Indian Pediatr. 2014;51:785\u2013800.","journal-title":"Indian Pediatr"},{"key":"2096_CR46","unstructured":"Typhibev Product Insert. Accessed on October 27, 2020. Available from: https:\/\/www.biologicale.com\/pdf\/Product_VB_International_Marketing.pdf"},{"key":"2096_CR47","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s12098-020-03504-8","volume":"87","author":"N Siddalingaiah","year":"2020","unstructured":"Siddalingaiah N, Tuluva T, Turaga K, et al. A multicentre single blind randomised controlled phase-II\/III study to evaluate immunogenicity and safety of single intramuscular dose of biological e\u2019s vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in healthy infants, children and adults in comparison with a licensed comparator. IAP ResRCHcon 2020 Abstracts. Indian J Pediatr. 2020; 87:974\u201388.","journal-title":"Indian J Pediatr"},{"key":"2096_CR48","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","volume":"36","author":"World Health Organization null","year":"2018","unstructured":"World Health Organization null. Rabies vaccines: WHO position paper, April 2018 \u2014 Recommendations. Vaccine. 2018;36:5500\u20133.","journal-title":"Vaccine"},{"key":"2096_CR49","unstructured":"Twinrab. Package Insert. Accessed on October 27, 2020. Available from: https:\/\/twinrab.com\/"},{"key":"2096_CR50","doi-asserted-by":"crossref","unstructured":"Kansagra K, Parmar D, Mendiratta SK, et al. A phase 3, randomised, open-label, non-inferiority trial evaluating anti-rabies monoclonal antibody cocktail (TwinrabTM) against human rabies immunoglobulin (HRIG) [published online ahead of print, 2020 Jun 17]. Clin Infect Dis. 2020; ciaa779.","DOI":"10.2139\/ssrn.3463307"},{"key":"2096_CR51","unstructured":"Tetraxim. Package Insert. Accessed on: October 27, 2020. Available from: https:\/\/www.sanofi.in\/-\/media\/Project\/One-Sanofi-Web\/Websites\/Asia-Pacific\/Sanofi-IN\/Home\/science-and-innovation\/for-healthcare-professionals\/product-information\/Tetraxim-API.pdf?la=en"},{"key":"2096_CR52","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.vaccine.2005.12.009","volume":"24","author":"JM Jacquet","year":"2006","unstructured":"Jacquet JM, B\u00e9gu\u00e9 P, Grimprel E, et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine. 2006;24:2440\u20138.","journal-title":"Vaccine"},{"key":"2096_CR53","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/PAS.0000000000000441","volume":"39","author":"C Ma","year":"2015","unstructured":"Ma C, Park JY, Montgomery EA, et al. A Comparative Clinicopathologic Study of Collagenous Gastritis in Children and Adults: The Same Disorder With Associated Immune-mediated Diseases. Am J Surg Pathol. 2015; 39:802\u201312.","journal-title":"Am J Surg Pathol"},{"key":"2096_CR54","unstructured":"Gavi-supported PCV profiles to support country decision making Pneumococcal and Rotavirus Working Group Gavi Secretariat and partners, July 2020. Accessed October 30,2020. Available at https:\/\/www.gavi.org\/sites\/default\/files\/document\/2020\/Gavi-PCV-vaccines-profiles-july-2020.pdf"},{"key":"2096_CR55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.vaccine.2019.08.072","volume":"38","author":"E Clarke","year":"2020","unstructured":"Clarke E, Bashorun AO, Okoye M, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1\/2 randomized, double-blinded, controlled trial. Vaccine. 2020;38: 399\u2013410.","journal-title":"Vaccine"},{"key":"2096_CR56","unstructured":"Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants \u2014 Full Text View \u2014 ClinicalTrials.gov [Internet]. [cited 2020 Oct 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03197376"},{"key":"2096_CR57","unstructured":"Pneumosil [DCGI Package insert].Mumbai, India: Serum Institute of India Pvt Ltd; 2020."},{"key":"2096_CR58","unstructured":"Pneumosil [WHO Package insert]. Mumbai, India: Serum Institute of India Pvt Ltd; 2020. Accessed on: October 27, 2020. Available from: https:\/\/www.path.org\/media-center\/new-pneumococcal-vaccine-serum-institute-india-achieves-who-prequalification\/"}],"container-title":["Indian Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-021-2096-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13312-021-2096-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-021-2096-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T03:51:15Z","timestamp":1744084275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13312-021-2096-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,29]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s13312-021-2096-7","relation":{},"ISSN":["0019-6061","0974-7559"],"issn-type":[{"value":"0019-6061","type":"print"},{"value":"0974-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,29]]},"assertion":[{"value":"29 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}